Related references
Note: Only part of the references are listed.Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy
Taylor M. Weis et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
Tanja Cufer et al.
ONCOLOGIST (2020)
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)
A. Figueiredo et al.
PULMONOLOGY (2020)
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials
D. E. Magee et al.
ANNALS OF ONCOLOGY (2020)
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
Claudio Martin et al.
CLINICAL LUNG CANCER (2020)
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
Ryo Morita et al.
LUNG CANCER (2020)
Real-World Evidence in Oncology: Opportunities and Limitations
Massimo Di Maio et al.
ONCOLOGIST (2020)
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
Karim Amrane et al.
CANCER MEDICINE (2020)
Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap
Arnoud J. Templeton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
Fabrice Barlesi et al.
ONCOIMMUNOLOGY (2020)
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
Beung-Chul Ahn et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
Lucio Crino et al.
ONCOLOGIST (2019)
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice
Doran Ksienski et al.
LUNG CANCER (2019)
Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer
Sean Khozin et al.
CANCER (2019)
Lung cancer and immunotherapy: a real-life experience from second line and beyond
Fady El Karak et al.
FUTURE ONCOLOGY (2019)
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya et al.
INVESTIGATIONAL NEW DRUGS (2019)
Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia
Urska Janzic et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2019)
Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice
Marc Montana et al.
JOURNAL OF CHEMOTHERAPY (2019)
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer
Francesco Grossi et al.
EUROPEAN JOURNAL OF CANCER (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following US Regulatory Approval
Sean Khozin et al.
ONCOLOGIST (2019)
A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice
Macarena Merino Almazan et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2019)
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
Elizabeth Dudnik et al.
LUNG CANCER (2018)
Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis
Keigo Kobayashi et al.
CLINICAL LUNG CANCER (2018)
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Daichi Fujimoto et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
Shu-Yung Lin et al.
JOURNAL OF CANCER (2018)
Survival As a Quality Metric of Cancer Care: Use of the National Cancer Data Base to Assess Hospital Performance
Lawrence N. Shulman et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group
Ales Ryska et al.
ONCOLOGIST (2018)
Rea world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort
R. A. Juergens et al.
CURRENT ONCOLOGY (2018)
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience
Ma Carmen Areses Manrique et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015
Susan Jin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michael Duruisseaux et al.
ONCOTARGET (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement
Eduard Vrdoljak et al.
ONCOLOGIST (2016)
Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study
Silvia Francisci et al.
EUROPEAN JOURNAL OF CANCER (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
K. M. Kerr et al.
ANNALS OF ONCOLOGY (2014)
Update on systemic therapy of advanced non-small-cell lung cancer
Tanja Cufer et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
